Blastomycosis News and Research

RSS

How did the COVID-19 pandemic impact the fungal infection hospitalization rates?

Researchers examined hospitalizations for fungal infections during the coronavirus disease 2019.

9 Jun 2023

Experts highlight the expanding presence and emerging risks from three endemic fungal diseases

Infectious diseases expert George Thompson has been studying and treating fungal diseases for over two decades. He monitors their spread, symptoms and relative risks.

22 Nov 2022

Increased distribution of fungal infections throughout the U.S.

Researchers update the geographic distribution of these species throughout the U.S.

21 Nov 2022

ATS publishes clinical guideline on laboratory diagnosis of fungal infections

The American Thoracic Society has published an official clinical guideline on laboratory diagnosis of fungal infections in pulmonary and critical care medicine in the Society's Aug. 30 American Journal of Respiratory and Critical Care Medicine.

30 Aug 2019

Fungal infection study identifies specific genetic vulnerability among Hmong people

Ten years ago, in Marathon County, Wisconsin, 55 people were sickened by an uncommon fungal infection called blastomycosis. Thirty patients were hospitalized. Two people died.

16 Jul 2019

FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality.

24 Sep 2014

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

The American Thoracic Society has released a new official clinical policy statement on the treatment of fungal infections in adult pulmonary and critical care patients.

4 Jan 2011

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

5 Sep 2008

Gamma interferon could aid fight against fungal infections

Interferon, the "superhero" cure for viral infections, may be a strong weapon in the battle against fungal infections in immunocompromised patients, according to an article in the November issue of Microbiology Today.

1 Nov 2007